Journal article
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study
GL Borromeo, C Brand, JG Clement, M McCullough, W Thomson, E Flitzanis, JD Wark
BMC Musculoskeletal Disorders | BMC | Published : 2011
Abstract
Background: Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than..
View full abstractGrants
Awarded by Novartis Pharmaceuticals Corporation
Funding Acknowledgements
This study is funded by the National Health and Medical Research Council (Project number 454683) and part-funded by a grant-in-aid from Novartis Pharmaceuticals.